Chemomab shareholders approve directors, capital and auditor

Chemomab Therapeutics Ltd. reported the results of its annual general shareholders meeting, which was originally scheduled for April 28, 2026 and adjourned to May 5, 2026 in Israel.

Rhea-AI Filing Summary

Chemomab Therapeutics Ltd. reported the results of its annual general shareholders meeting, which was originally scheduled for April 28, 2026 and adjourned to May 5, 2026 in Israel.

Shareholders approved the re-election of Mr. Neil Cohen and Dr. Claude Nicaise as Class II directors, a compensation policy for office holders and directors, an increase in the company’s authorized share capital with a related amendment to its articles of association, and the re-appointment of Somekh Chaikin (a KPMG member firm) as independent registered public accounting firm for the fiscal year ended December 31, 2026.

Key Figures

Annual meeting date: May 5, 2026 Original meeting date: April 28, 2026 Fiscal year for auditor appointment: Year ended December 31, 2026 +2 more

5 metrics

Annual meeting date May 5, 2026 Adjourned annual general shareholders meeting date in Israel

Original meeting date April 28, 2026 Initial scheduled date for the annual general shareholders meeting

Fiscal year for auditor appointment Year ended December 31, 2026 Term for which Somekh Chaikin was re-appointed as auditor

Form F-3 file numbers 333-275002, 333-281750 Registration statements into which this Form 6-K is incorporated

Form S-8 file numbers 333-259489, 333-266868 Employee benefit registration statements incorporating this Form 6-K

Key Terms

compensation policy for office holders and directors, authorized share capital, articles of association, independent registered public accounting firm, +2 more

6 terms

compensation policy for office holders and directors financial

"the approval of the compensation policy for office holders and directors"

authorized share capital financial

"the approval of an increase of the Company’s authorized share capital"

The maximum number of shares a company is legally allowed to issue according to its governing documents. Think of it as the size of the blank checkbook a company keeps for selling ownership stakes: it sets an upper limit but does not mean all shares are in circulation. Investors care because a larger authorized amount makes it easier for the company to raise money or grant stock-based pay, which can dilute existing holdings and affect control and value per share.

articles of association regulatory

"and to amend the Company’s Articles accordingly"

A company's articles of association are its written rulebook that sets how the business is run, how decisions are made, and what rights owners and directors have—covering voting, meetings, appointment and removal of directors, share classes and dividend policies. For investors, these rules matter because they determine how easily control can change, what protections minority owners have, and how corporate actions (like issuing new shares or changing leadership) are approved, much like a home’s bylaws shaping what residents can and cannot do.

independent registered public accounting firm financial

"as the Company’s independent registered public accounting firm"

An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.

Israeli Companies Law, 5759-1999 regulatory

"by the requisite majority in accordance with the Israeli Companies Law, 5759-1999"

Registration Statements on Form F-3 and Form S-8 regulatory

"incorporated by reference into the Company’s Registration Statements on Form F-3 ... and Form S-8"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Chemomab Therapeutics (CMMB) shareholders approve at the 2026 annual meeting?

Shareholders approved director re-elections, a new compensation policy, an increase in authorized share capital with related Articles amendments, and the re-appointment of Somekh Chaikin (KPMG member firm) as independent auditor for the fiscal year ended December 31, 2026.

Which directors were re-elected at Chemomab Therapeutics’ 2026 shareholders meeting?

Shareholders re-elected Mr. Neil Cohen and Dr. Claude Nicaise as Class II directors. Their re-election was approved in accordance with Israeli Companies Law and the company’s articles of association, following the proposals described in Chemomab’s proxy statement for the 2026 meeting.

What compensation changes did Chemomab Therapeutics (CMMB) approve in this 6-K?

Shareholders approved a compensation policy for office holders and directors. This policy was proposed in the company’s proxy statement for the 2026 annual general meeting and adopted in accordance with Israeli Companies Law and Chemomab’s articles of association.

Did Chemomab Therapeutics (CMMB) change its authorized share capital?

Yes. Shareholders approved an increase in Chemomab’s authorized share capital and a related amendment to its articles of association. The specific terms were described in the proxy statement referenced in the Form 6-K report for the 2026 meeting.

Who is Chemomab Therapeutics’ independent auditor for the 2026 fiscal year?

Shareholders re-appointed Somekh Chaikin, a member firm of KPMG International, as Chemomab’s independent registered public accounting firm for the fiscal year ended December 31, 2026, as proposed in the company’s proxy statement for the annual meeting.

How is this Chemomab Therapeutics 6-K linked to its registration statements?

This Form 6-K is incorporated by reference into Chemomab’s registration statements on Form F-3 (File Nos. 333-275002 and 333-281750) and Form S-8 (File Nos. 333-259489 and 333-266868), allowing those registration statements to include the disclosed meeting results.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/06/2026 - 05:03 PM EDT Learn about SEC filing dates

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2026

Commission File Number 001-38807

CHEMOMAB THERAPEUTICS LTD.
(Translation of registrant’s name into English)

10 Habarzel Street, Building C, 10th Floor, Tel-Aviv, Israel 

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒     Form 40-F ☐

EXPLANATORY NOTE

Chemomab Therapeutics Ltd. (the “Company”) hereby furnishes the results of its annual general shareholders meeting (the “Meeting”), which was scheduled for April 28, 2026 and adjourned to May 5, 2026, at 4:30 p.m. (Israel time), at Meitar | Law Offices, located at 16 Abba Hillel Road, 10th floor, Ramat Gan 5250608, Israel.

At the Meeting, the Company’s shareholders voted upon and approved, by the requisite majority in accordance with the Israeli Companies Law, 5759-1999, and the Company’s articles of association (the “Articles”), the following proposals: (i) the re-election of each of Mr. Neil Cohen and Dr. Claude Nicaise as Class II directors, (ii) the approval of the compensation policy for office holders and directors, (iii) the approval of an increase of the Company’s authorized share capital and to amend the Company’s Articles accordingly, and (iv) the re-appointment of Somekh Chaikin, a member firm of KPMG international, as the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2026; all in accordance with the Company’s proxy statement related to the Meeting, which was attached as Exhibit 99.1 to the Company’s Report of Foreign Private Issuer on Form 6-K furnished to the Securities and Exchange Commission on March 20, 2026.

This Form 6-K is incorporated by reference into the Company’s Registration Statements on Form F-3 (File No. 333-275002 and 333-281750) and Form S-8 (File No. 333-259489 and No. 333-266868).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CHEMOMAB THERAPEUTICS LTD.
Date: May 6, 2026	By:	/s/ Sigal Fattal
		Sigal Fattal
		Chief Financial Officer